ATE293169T1 - Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen - Google Patents
Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machenInfo
- Publication number
- ATE293169T1 ATE293169T1 AT02729440T AT02729440T ATE293169T1 AT E293169 T1 ATE293169 T1 AT E293169T1 AT 02729440 T AT02729440 T AT 02729440T AT 02729440 T AT02729440 T AT 02729440T AT E293169 T1 ATE293169 T1 AT E293169T1
- Authority
- AT
- Austria
- Prior art keywords
- latency
- pharmaceutically active
- fusion protein
- nucleic acid
- construct
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 abstract 5
- 102000037865 fusion proteins Human genes 0.000 abstract 5
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 101800001155 Latency-associated peptide Proteins 0.000 abstract 2
- 102400000401 Latency-associated peptide Human genes 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000006337 proteolytic cleavage Effects 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0100551.1A GB0100551D0 (en) | 2001-01-09 | 2001-01-09 | Protein |
| US09/756,283 US6942853B2 (en) | 2001-01-09 | 2001-01-09 | Latent fusion protein |
| PCT/GB2002/000068 WO2002055098A2 (en) | 2001-01-09 | 2002-01-09 | Latency associated peptide for providing latency to pharmaceutically active proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE293169T1 true ATE293169T1 (de) | 2005-04-15 |
Family
ID=26245544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02729440T ATE293169T1 (de) | 2001-01-09 | 2002-01-09 | Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6942853B2 (de) |
| EP (1) | EP1349944B1 (de) |
| JP (1) | JP4201253B2 (de) |
| AT (1) | ATE293169T1 (de) |
| AU (1) | AU2002219345B2 (de) |
| DE (1) | DE60203692T2 (de) |
| DK (1) | DK1349944T3 (de) |
| ES (1) | ES2240740T3 (de) |
| GB (1) | GB0100551D0 (de) |
| WO (1) | WO2002055098A2 (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7141392B2 (en) * | 2001-01-09 | 2006-11-28 | Queen Mary And Westfield College | Latent fusion protein |
| EP1572908A4 (de) * | 2002-02-14 | 2008-10-22 | William J Rutter | Chimäre moleküle zur spaltung in einem behandelten wirt |
| CA2624802A1 (en) * | 2005-10-04 | 2007-04-19 | Greenville Hospital System | Latent procytotoxins and uses thereof |
| DE102006009324A1 (de) | 2006-03-01 | 2007-09-06 | Dr.Ing.H.C. F. Porsche Ag | Verfahren und Steuergerät zur Steuerung eines variablen Turbolader-Turbinenströmungsquerschnitts |
| CA2667637C (en) | 2006-10-31 | 2021-04-20 | East Carolina University | Fusion proteins comprising an anti-inflammatory cytokine and an antigen for treatment of immune disorders |
| GB0724556D0 (en) * | 2007-12-17 | 2008-01-30 | Queen Mary & Westfield College | LAtency associated protein construct with aggrecanase sensitive cleavage site |
| FR2932190A1 (fr) | 2008-06-10 | 2009-12-11 | Commissariat Energie Atomique | Peptides cycliques fluorescents, procedes de preparation de ceux-ci et utilisation de ces peptides pour mesurer l'activite enzymatique d'une enzyme protease |
| EP3348275A3 (de) | 2009-03-31 | 2018-10-24 | East Carolina University | Cytokine und neuroantigene zur behandlung von immunerkrankungen |
| GB0911365D0 (en) | 2009-06-30 | 2009-08-12 | Bioceramic Therapeutics Ltd | Multicomponent glasses for use as coatings and in personal care products |
| EP2553101A4 (de) | 2010-04-02 | 2013-09-04 | Univ Rochester | Proteaseaktivierte zytokine |
| EP2878308B1 (de) * | 2013-12-02 | 2018-10-31 | Thomas Harder | Mittel und Verfahren zur Unterdrückung der T-Zell-Aktivierung |
| GB201411506D0 (en) | 2014-06-27 | 2014-08-13 | Univ London Queen Mary | Modified latency associated protein construct |
| JP6516235B2 (ja) * | 2014-10-31 | 2019-05-22 | 国立大学法人富山大学 | キメラタンパク質及びそれを用いたミクログリア活性阻害剤 |
| AU2019271148B9 (en) | 2018-05-14 | 2025-05-29 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| BR112020023118A2 (pt) | 2018-05-14 | 2021-04-13 | Werewolf Therapeutics, Inc. | Polipeptídeos de interleucina 12 ativáveis e métodos de uso destes |
| WO2020023702A1 (en) | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| EP3856764A4 (de) * | 2018-09-27 | 2022-11-02 | Xilio Development, Inc. | Maskierte cytokin-polypeptide |
| ES2780274A1 (es) * | 2019-02-15 | 2020-08-24 | Consejo Superior De Investig Científicas (Csic) | Cortistatina o un análogo de la misma como agente farmacéuticamente activo en forma latente |
| WO2020232305A1 (en) | 2019-05-14 | 2020-11-19 | Werewolf Therapeutics, Inc. | Separation moieties and methods and use thereof |
| US11845801B2 (en) | 2019-06-12 | 2023-12-19 | AskGene Pharma, Inc. | IL-15 prodrugs and methods of use thereof |
| EP4058471A1 (de) | 2019-11-14 | 2022-09-21 | Werewolf Therapeutics, Inc. | Aktivierbare cytokin-polypeptide und verfahren zur verwendung davon |
| GB202004679D0 (en) | 2020-03-31 | 2020-05-13 | Stealthyx Therapeutics Ltd | Modified latercy associated protein construct |
| CA3174786A1 (en) * | 2020-04-10 | 2021-10-14 | Sayantan Mitra | Activatable cytokine constructs and related compositions and methods |
| KR20230113581A (ko) | 2020-11-25 | 2023-07-31 | 실리오 디벨럽먼트, 인크. | 종양 특이적 절단성 링커 |
| BR112023018735A2 (pt) | 2021-03-16 | 2023-11-28 | Cytomx Therapeutics Inc | Construtos de citocinas ativáveis mascarados e composições e métodos relacionados |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5284763A (en) | 1985-03-22 | 1994-02-08 | Genentech, Inc. | Nucleic acid encoding TGF-β and its uses |
| CA2003886A1 (en) | 1988-12-16 | 1990-06-16 | Anthony F. Purchio | Cloning and expression of simian transforming growth factor-beta 1 |
| AU639047B2 (en) | 1989-11-22 | 1993-07-15 | Genentech Inc. | Latency associated peptide and uses therefor |
| US5697901A (en) | 1989-12-14 | 1997-12-16 | Elof Eriksson | Gene delivery by microneedle injection |
| EP1770161A3 (de) | 1993-05-12 | 2008-04-23 | Genetics Institute, LLC | BMP-11 Zusammenstellungen |
| EP0704532B1 (de) | 1994-06-10 | 2002-09-11 | United States Surgical Corporation | Rekombinante Chimäre Proteine und Verfahren zur deren Verwendung |
| US5800811A (en) * | 1995-06-06 | 1998-09-01 | Hall; Frederick L. | Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site |
| EP0854929A1 (de) * | 1995-09-27 | 1998-07-29 | Medical Research Council | Rekombinante viren, die ein bei einer protease spaltbares protein enthalten |
| DE19701141C1 (de) | 1997-01-16 | 1998-04-09 | Hoechst Ag | Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen |
| JP4566290B2 (ja) * | 1997-04-30 | 2010-10-20 | ツインストランド・ホールディングス・インコーポレイテッド | 癌、ウイルスまたは寄生虫感染を治療するためのリシン様毒素変異体 |
| GB2324960A (en) | 1997-05-09 | 1998-11-11 | Univ Manchester | Delivery of naked DNA for wound healing |
| EP2128260A3 (de) | 1998-10-07 | 2010-06-16 | STRYKER CORPORATION (a Michigan corporation) | Modifizierte TGF-beta-Superfamilienproteine |
| EP1322785A4 (de) * | 2000-09-11 | 2005-11-09 | Univ Columbia | Kombinatorische fluoreszenzenergietransfer-tags und deren verwendungen |
-
2001
- 2001-01-09 US US09/756,283 patent/US6942853B2/en not_active Expired - Lifetime
- 2001-01-09 GB GBGB0100551.1A patent/GB0100551D0/en not_active Ceased
-
2002
- 2002-01-09 EP EP02729440A patent/EP1349944B1/de not_active Expired - Lifetime
- 2002-01-09 JP JP2002555832A patent/JP4201253B2/ja not_active Expired - Fee Related
- 2002-01-09 AU AU2002219345A patent/AU2002219345B2/en not_active Ceased
- 2002-01-09 DE DE60203692T patent/DE60203692T2/de not_active Expired - Lifetime
- 2002-01-09 ES ES02729440T patent/ES2240740T3/es not_active Expired - Lifetime
- 2002-01-09 AT AT02729440T patent/ATE293169T1/de not_active IP Right Cessation
- 2002-01-09 DK DK02729440T patent/DK1349944T3/da active
- 2002-01-09 WO PCT/GB2002/000068 patent/WO2002055098A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP4201253B2 (ja) | 2008-12-24 |
| ES2240740T3 (es) | 2005-10-16 |
| DK1349944T3 (da) | 2005-07-25 |
| WO2002055098A2 (en) | 2002-07-18 |
| EP1349944B1 (de) | 2005-04-13 |
| GB0100551D0 (en) | 2001-02-21 |
| JP2004520031A (ja) | 2004-07-08 |
| US6942853B2 (en) | 2005-09-13 |
| DE60203692T2 (de) | 2006-03-02 |
| US20020151478A1 (en) | 2002-10-17 |
| EP1349944A2 (de) | 2003-10-08 |
| WO2002055098A3 (en) | 2002-11-21 |
| DE60203692D1 (de) | 2005-05-19 |
| AU2002219345B2 (en) | 2006-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE293169T1 (de) | Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen | |
| ATE500323T1 (de) | Subtilisin-variante | |
| EA200300381A1 (ru) | Нуклеиновые кислоты и полипептиды нового рецептора | |
| AR008727A1 (es) | COMPOSICIONES Y PROTEINAS DE FUSIoN QUE COMPRENDEN UN POLIPEPTIDO QUE COMPRENDE UNA PORCION INMUNOGENICA DE UNA PROTEINA DE PROSTATA O SU VARIANTE, Y USOS DE LAS MISMAS PARA PREPARAR UN MEDICAMENTO | |
| YU8997A (sh) | Prečišćen protein koji ima serinsku proteaznu inhibitorsku aktivnost i farmaceutski preparat koji ga sadrži | |
| WO2002014358A3 (en) | Novel secreted proteins and their uses | |
| BR9814276A (pt) | Antìgenos de superfìcie | |
| WO2002008277A3 (en) | Nucleic acids, vectors, host cells, polypeptides, and uses thereof | |
| AU2003222717A8 (en) | Streptavidin-binding peptide | |
| DK1025236T3 (da) | Human checkpoint kinase, HCDS1, præparater og fremgangsmåde | |
| WO2004054607A3 (de) | Stabile therapeutische proteine | |
| DE69941433D1 (de) | Von protease typ ii spaltbares peptid | |
| WO2002022662A3 (en) | Insect inhibitory bacillus thuringiensis proteins, fusions, and methods of use therefor | |
| DK1904529T3 (da) | Anvendelse af Stefin A som et scaffoldprotein | |
| ATE503834T1 (de) | Bibliotheken rekombinanter chimärischer proteine | |
| Godat et al. | Inhibition of a cathepsin L-like cysteine protease by a chimeric propeptide-derived inhibitor | |
| WO2004053117A3 (en) | Serine protease | |
| WO2002016578A3 (en) | Secreted proteins and methods of using same | |
| WO2002012475A3 (en) | C1q-related factor, homologous polypeptides and therapeutic uses thereof | |
| ATE278011T1 (de) | Human dnase ii | |
| DE60015559D1 (de) | Sentrin-spezifische menschliche protease senp1 | |
| FR2813606B1 (fr) | Proteine bard1 tronquee, et ses applications diagnostiques et therapeutiques | |
| ATE427355T1 (de) | Menschliche alpha2-delta4-calciumkanal- untereinheit codierende cdna | |
| TH62241A (th) | ไบคูนินของคน | |
| WO2002000709A3 (en) | Cerebellin homologous polypeptides and therapeutic uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |